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Abstract  
Implantable ‘structural bridges’ based on nanofabricated polymer scaffolds have great 
promise to aid spinal cord regeneration. Their development (optimal formulations, surface 
functionalizations, biocompatibility, topographical influences and degradation profiles) is 
heavily reliant on live animal injury models. These have several disadvantages including 
invasive surgical procedures, ethical issues, high animal usage, technical complexity and 
expense. In vitro 3-D organotypic slice arrays could offer a novel solution to overcome these 
challenges, but their utility for nanomaterials testing is undetermined. We have developed an 
in vitro model of spinal cord injury that replicates stereotypical cellular responses to 
neurological injury in vivo, viz. reactive gliosis, microglial infiltration and limited nerve fibre 
outgrowth. We describe a facile method to safely incorporate aligned, poly-lactic acid 
nanofiber meshes (± poly-lysine + laminin coating) within injury sites using a lightweight 
construct. Patterns of nanotopography induced outgrowth/alignment of astrocytes and 
neurons in the 'dish model' were strikingly similar to that induced by comparable materials in 
related studies in vivo. This highlights the value of our model in providing biologically-
relevant readouts of the regeneration-promoting capacity of synthetic bridges within the 
complex environment of spinal cord lesions. Our approach can serve as a prototype to 
develop versatile bio-screening systems to identify materials/combinatorial strategies for 
regenerative medicine, whilst reducing live animal experimentation.  
Keywords: organotypic slice culture, spinal cord injury, in vitro model, electrospinning, 
aligned nanofiber, 3 R’s. 
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1. Introduction 
The implantation of nanofiber scaffolds to serve as synthetic ‘structural bridges’ is an 
approach with high regenerative potential following injury in a range of tissue systems, 
notably spinal cord injury (SCI) [1]. The latter is a destructive, multifaceted condition, with a 
poor clinical prognosis for functional recovery [2,3].
 
Strategically, such scaffolds can aid 
regeneration by providing aligned topographies, gradients of chemical guidance cues and 
transplant cell populations to replace lost/damaged cells [4–6]. Evaluation and optimization 
of synthetic bridges is currently the subject of intensive research globally, with the 
developmental testing of novel scaffolds and constructs being heavily reliant on live animal 
injury models [7].  
There are several ethical and practical drawbacks relating to animal experimentation in this 
context. The production of injury models can be a highly invasive and time consuming 
process, usually requiring high technical expertise. Depending on the model, the procedures 
can result in serious adverse effects such as infections, paralysis or other movement 
disorders, bladder dysfunction and so on [7].
 
Even in the hands of a skilled operator, surgical 
procedures can inherently generate significant inter-animal variability, requiring large animal 
group sizes for statistical validity [7].
 
Following lesion (injury) induction, introduction of 
synthetic scaffolds into injury areas usually requires re-anesthetization, with the second 
procedure involving similar risks to injury induction. In vivo models necessitate the use of 
analgesia and rigorous post-operative monitoring of animals, which must be housed 
individually [8]. The requirements for specialist staff and infrastructure in particular, place 
major financial constraints on such work [9,10]. 
Considerations of this nature have prompted the current global drive for the Reduction, 
Replacement and Refinement of animal experimentation (the 3R’s principles) [11]. In 
particular, there is a major current need to develop facile, high throughput in vitro models 
*Manuscript
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that: (i) mimic pathological features of injury sites in vivo (and therefore have biological 
validity); (ii) are compatible with introduction of nano-engineered constructs for the robust 
and reproducible testing of the latter; and (iii) induce comparable cellular responses to the 
introduced materials as those in live animal injury models [12].  
Models possessing such features can be predicted to reduce animal usage and suffering, as 
well as costs and technical difficulty, thereby facilitating the screening of pro-regenerative 
materials for nanomedicine. Despite the need for such biologically relevant testing systems, 
‘reductionist models’ described to-date typically lack the ability to mimic multifaceted 
components of SCI pathology and the complexities of cytoarchitecture in vivo. The central 
nervous system (CNS; i.e. the brain and spinal cord) is a particularly challenging tissue 
system in this regard, due to the complex cellular dynamics and intricate (cardinal) 
pathophysiological events displayed after neurological injury [13]. For example, following 
SCI in vivo: astrocytes upregulate expression of the astrocyte-specific marker glial fibrillary 
acidic protein (GFAP), within and adjacent to lesions, to form a scar that constitutes a critical 
barrier to axonal regeneration [14]; microglia (the immune-competent cells of the CNS) 
infiltrate into lesion sites and are responsible for the breakdown and phagocytosis of cellular 
debris and toxic substances following injury [15,16]; and limited, spontaneous sprouting of 
nerve fibers occurs from lesion margins, with the extent of regeneration declining with age 
[17].  
In this context, 3-D, multicellular organotypic slice cultures (slices of immature tissue that 
develop comparably to the donor organ in an ex vivo environment) could offer a unique 
solution to the above challenges. For example, such tissue arrays are increasingly being used 
for long term, high throughput assays in experimental neurology [18].
 
They provide a 
versatile bridge between isolated cell culture and in vivo experiments wherein the 
cytoarchitecture and structural relationships of cells are maintained, allowing for parameters 
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of neural regeneration, e.g. neuronal survival [19], nerve fiber regeneration [20,21]
 
and 
collateral axon sprouting to be evaluated [22]. These models offer several advantages 
including the ease of manipulation/observation of in vitro preparations [18]; several ages, 
neuroanatomical areas and species, including human foetuses [23]
 
and transgenic models 
[24,25]
 
can be used as tissue donor sources, offering high flexibility to study neural 
pathologies and disease mechanisms. Slice cultures are amenable to electrophysiological 
techniques [26],
 
molecular biology methods [27], time lapse video microscopy [28] and 
dynamic confocal imaging [10,29,30], which has greatly expanded the translational utility of 
this approach. Clearly therefore, such models have wide applicability to a range of tissues and 
pathologies. Despite their critical advantages, to the best of our knowledge, such models have 
never been utilized to examine the interactions of nano-materials with cells in an injury-
simulated environment.  
To address this issue, we have established a prototype slice model in vitro, which combines 
for the first time, a tissue injury paradigm with delivery of pro-regenerative scaffolds. To 
achieve this, we first describe a reproducible method to induce a focal injury in spinal cord 
slices; the basic pathological features of these injuries in vitro have been evaluated to 
establish their overall relevance to in vivo pathology. We then present a novel methodology 
to incorporate aligned nanofiber scaffolds across injury foci to evaluate the topographical 
influence on neural cell responses within injury sites.  
2. Materials and Methods 
2.1. Materials. Tissue culture plastics, culture media and supplements were from Sigma-
Aldrich (Poole, UK) and Fisher Scientific (Loughborough, UK). Omnipore membranes 
(JHWP04700) and Millicell culture inserts were from Millipore (Watford, UK). The 
live/dead cell viability kit was from Invitrogen (Paisley, UK) and Vectashield mounting 
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medium with DAPI (4’, 6-diamidino-2-phenylindole) from Vector Laboratories 
(Peterborough, UK). Primary antibodies were: rabbit and mouse anti-neuronal class III β-
tubulin (clone TUJ-1, Covance, Princeton, NJ), rabbit anti-GFAP (DakoCytomation, Ely, 
UK), biotin-conjugated anti-lectin (from Lycopersicon esculentum, tomato; Sigma-Aldrich, 
UK). Cy3- and FITC-conjugated AffiniPure secondary antibodies were from Jackson 
ImmunoResearch Laboratoratories Inc. (West Grove, PA, USA); FITC-conjugated anti-biotin 
secondary antibody was from Sigma-Aldrich (UK). Poly-L,D-lactic acid (PLA; 96% L: 4% 
D) was from Purac biochem BV (Gorinchem, Netherlands) and chloroform, 
dimethylformamide and rhodamine B from Sigma-Aldrich (UK). Collagen type I solution 
was from BD Biosciences (UK). 
 
2.2. Production of Organotypic Spinal Cord Slice Cultures. The care and use of animals 
was in accordance with the Animals (Scientific Procedures) Act of 1986 (United Kingdom) 
with local ethics committee approval. Spinal cords derived from mouse pups aged 0 - 6 
postnatal days (P0 - P6) were rapidly removed after decapitation and transferred into ice-cold 
slicing medium (EBSS buffered with 25mM HEPES) [31–33]. Longitudinal slices (350 µm) 
were prepared using a McIlwain tissue chopper. Two/three slices were transferred to 
Omnipore membrane ‘confetti,’ resting on the Millicell culture insert membrane. Slices were 
cultured at the air-medium interface with culture medium (50% MEM, 25% heat-inactivated 
horse serum, 25% EBSS supplemented with 36 mM D-glucose, 100 U/mL penicillin, 100 
µg/mL streptomycin and 250 ng/mL amphotericin B) for up to 16 days in vitro (DIV; Figure 
1A1 and A2). Cultures were incubated in humidified 95% O2/5% CO2 at 37
o
C with 80% 
medium changes every two days. In all cases the number of experiments, n, refers to slices 
obtained across different animals and litters. 
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2.3. Immunocytochemistry. Slices were washed in phosphate buffered saline (PBS) before 
and after fixation with 4% paraformaldehyde [PFA; 20 min; room temperature (RT)]. 
Samples were incubated in blocking solution consisting of 5% normal donkey serum (10% 
for lectin antibodies) in PBS, with 0.3% Triton X-100 for TUJ-1 and GFAP staining (30 min; 
RT). Incubations with primary antibodies in blocking solution followed (lectin 1:200, GFAP 
1:500; TUJ-1 1:1000; 24 hours at RT or 4
o
C). Following PBS washes samples were 
incubated with appropriate Cy3- and/or- FITC-conjugated secondary antibodies (4 h at RT or 
4
o
C). Slices were subsequently washed with PBS and mounted with Vectashield mounting 
medium containing DAPI. 
 
2.4. Fluorescence Imaging and Statistical Analysis. Slices were visualized on an Axio 
Scope A1 fluorescence microscope (Carl Zeiss MicroImaging GmbH; Germany) fitted with 
an Axio Cam ICc1 digital camera and AxioVision software. Where applicable, fluorescence 
images of immunostained slices were merged using Photoshop CS5.1 (version 12.1). 
GraphPad Prism v5.0 software was used for all statistical analyses performed. All values 
quoted are expressed as the mean ± standard error of the mean (SEM), unless otherwise 
stated. Data were analyzed by a one-way analysis of variance, using Bonferroni’s multiple 
comparison test for post-hoc analysis; a Bartlett's test was performed to examine 
homogeneity of variance and, where necessary, data were transformed (square root or log) 
prior to analysis.  
 
2.5. Assessment of Organotypic Spinal Cord Slice Viability after In Vitro Culture. For 
live/dead assays, intact slices (P0 - P5; n = 3) cultured for 6 – 16 DIV were washed three 
times with PBS. Slices were incubated with calcein (1 µL/mL) to label live cells and 
ethidium bromide (3 µL/mL) to label dead cells, for 15 minutes at 37
o
C. Following PBS 
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washes, slices were mounted with Vectashield mounting medium containing DAPI. 
Fluorescence micrographs of staining were captured with consistent exposure settings. The 
corrected integrated density (Supporting Information S1) was quantified using ImageJ 
software (version 1.45s; NIH) and the values for the live-stained micrograph expressed as a 
percentage of the sum total from both [30]. 
 
2.6. Lesioning Organotypic Spinal Cord Slice Cultures. To develop a reproducible focal 
lesioning method, a slice lesioning tool was developed in-house using a pre-assembled, 
double-bladed scalpel (Figure 1B). This was the product of several prototypes optimized to 
rapidly produce regular, evenly spaced lesion margins, whilst preventing drying of slices. The 
tool was aseptically assembled prior to lesioning by taping together two surgical blades (size 
15) secured into an empty scalpel holder (Figure 1B). To assess the reproducibility of 
lesioning tool construction, the diameter of lesions induced in slices was investigated across 
five litters (3 - 14 slices per litter; each litter representing independent assembly of the tool). 
Fluorescence micrographs of DAPI-stained slices were used to calculate the mean distance 
between lesion margins from each culture. 
The lesioning procedure was implemented inside a laminar flow hood using a dissection 
microscope at x12.5 magnification. To improve lesioning reproducibility, the shape of the 
confetti supporting slices (see Figure 1A3 and section 2.2) was re-designed to facilitate the 
use of forceps to grip both the culture insert wall and confetti together, thus stabilizing the 
slice. The lesioning tool was drawn through the slice and small lateral movements used to 
ensure the complete severing of nerve fiber tracts. The slice debris between the two lesion 
margins was subsequently removed using an aspirator, fitted with a 200 µl pipette tip. 
Cultures were lesioned at 1 - 8 DIV and were fixed within 7 days of lesioning. Slices 
generated in spinal cords derived from both ‘younger’ (P0 mice: lesioned after 1 DIV; fixed 7 
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days later) and ‘older’ (P5 mice: lesioned after 8 DIV; fixed 7 days later) slices with different 
extents of intrinsic nerve fiber outgrowth were used for characterizing the interaction of 
nanofibers with neuronal cells. 
 
2.7. Quantification of Astrogliosis at Lesion Margins (Supporting Information S2). P0 - P2 
slice cultures lesioned after 1 DIV, were fixed at 6 days post-lesioning and stained for GFAP. 
Slices were imaged with consistent exposure settings and converted to grayscale. Optical 
density (OD) profiles from the lesion margins were generated using ImageJ software and 
averaged to form a single profile for each slice. Baseline intensity values were obtained at ca 
1mm from the lesion site, where astrocytes displayed un-reactive morphologies and lower 
GFAP expression levels. A single, corrected OD profile from the lesion margins of each slice 
(n = 6) was produced by subtracting the baseline intensity from each value in the averaged 
trace and averaged with traces from five other slices. The differences in average OD in the 
zones 0 - 100 µm, 100 - 200 µm and > 200 µm from the lesion boundary were subsequently 
compared. 
 
2.8. Quantification of Microglial Infiltration into Lesion Sites. Spinal cords were extracted 
from P0 - P2 mice, lesioned after 2 DIV and fixed 0, 5 and 10 days post-lesioning. The 
numbers of lectin-positive (lectin
+
) microglia were counted within the lesion site of each 
slice, using a standard size grid overlaid onto each image. The total number of microglia per 
unit area per slice was averaged at each time point (n = 3). 
 
2.9. Fabrication and Characterization of Electrospun Nanofibers. A 2% (w/v) PLA 
solution was prepared by dissolving the polymer in chloroform prior to the addition of 
dimethylformamide (7:3 solvent volume ratio). The addition of rhodamine B into the solution 
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(0.1 mg/mL) produced fluorescent nanofibers. A parallel electrode collector (Figure 1C1) 
was used to obtain nanofibers in a highly aligned conformation over a 10 minute unit 
operation. Electrospinning parameters were kept constant for all experiments. A 
'densification' tool (Figure 1C2) was used as an intermediate processing step, to compact the 
nanofibers from the nanofiber deposition area of the collector (84 cm
2
) to that of the tool (13 
cm
2
), whilst maintaining the aligned nanofiber conformation. Nanofibers were then mounted 
onto acetate frames from the densification tool (Figure 1C3) and affixed using a spray 
adhesive, to be handleable and to maintain their aligned conformation for use in experiments. 
Nanofibers were desiccated overnight and sterilized in a UV chamber before use in all 
experiments. 
The diameter and line density (number of aligned nanofibers along a distance perpendicular 
to the axis of nanofiber orientation) of both fluorescent and non-fluorescent nanofibers used 
were determined from micrographs taken with a field emission scanning electron microscope 
(Supporting Information S3). 
 
2.10. Nanofiber Surface Treatment with Poly-D-Lysine and Laminin. Multiple sterile, 
portable nanofiber frames were rapidly incubated with poly-D-lysine and laminin solutions 
(herein termed PDL and LAM, respectively) on a chamber developed in-house (Figure 1C4). 
Coating solutions were applied sequentially (20 µg/mL PDL: 12 hours; 10 µg/mL LAM: 5 
hours) then washed with PBS and kept moist for placement over slice lesions. Fourier 
transform infrared spectroscopic analysis confirmed the presence of protein on the surface of 
treated nanofibers, verifying surface treatment procedures (Supporting Information S4). 
 
2.11. Incorporation of Nanofibers over Lesioned Slices. The technical challenge of 
incorporating delicate, aligned nanofibers over lesioned slices (Figure 1C5) was overcome by 
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gently positioning nanofiber-bearing frames parallel to the slice longitudinal axis using 
forceps. A 3 mg/mL neutralized collagen solution was applied around the acetate frame, to 
ensure stability for subsequent staining procedures. 
 
2.12. Axonal Outgrowth and Alignment across Lesions (± Nanofibers). Spinal cords 
derived from both ‘younger’ (P0 mice: lesion at 1 DIV) and ‘older’ (P5 mice: lesion at 8 
DIV) models were used to evaluate intrinsic nerve fiber outgrowth. Nerve fiber outgrowth 
density was quantified in TUJ-1 stained slices from both models ± nanofibers (Supporting 
Information S5). Fluorescence micrographs were obtained and OD profiles generated from 
regular intervals along the length of the lesion site using ImageJ software for peak analysis 
(Supporting Information S5). The average total number of peaks per mm
2
 was then calculated 
for each slice (n ≥ 3).  
To assess the alignment of TUJ-1
+
 nerve fibers with coated and uncoated nanofibers, the 
percentage of aligned TUJ-1
+
 nerve fibers was scored (n ≥ 3 per group) by two independent 
assessors blind to the treatment groups: five data bins, each with a range of 20%, were used 
to classify any potential alignment observed. 
 
3. Results 
 
3.1. Slice Preparation and Lesion Induction 
The viability of intact slices quantified using fluorescence microscopy (Supporting 
Information S1) was found to be approximately 96% ± 2%, with a representative slice shown 
in Figure 2A. Dead cells generated by the slicing procedure were typically found at the slice 
edges [34].  
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Following the optimization of the lesioning procedure, a complete transecting lesion could 
be induced in slices with a double-bladed scalpel, ensuring the severing of nerve fibers across 
the lesion. In contrast, the use of single-blade cutting instruments, e.g. conventional scalpels, 
to produce the same injury requires two sequential transecting motions, which increases the 
procedural difficulty/duration and lesion size variability, whilst restricting the minimum 
possible lesion size to approximately 750 µm (data not shown). The tissue between the cut 
edges could be efficiently removed to reveal distinct lesion margins and to enable the 
visualization of regenerative events across lesion sites (Figure 2B). Measurements of induced 
lesions revealed a mean distance of 439 µm between lesion margins, which was highly 
reproducible (± 4 µm; coefficient of variation = 2 %) across five separate cultures, each 
representing separate occasions of tool assembly (Figure 2C). Increasing the inter-blade 
distance concomitantly increased the lesion area, thereby increasing the versatility of the 
injury model in terms of severity and to accommodate a range of potential scaffold sizes. 
Live/dead staining of lesioned slices 7 days post-injury (Figure 2D) demonstrated that the 
procedures did not significantly impact overall slice viability for further experimentation, as 
evidenced by a central band of live cells with few dead cells interspersed around the area of 
injury. 
 
3.2. Characterization of Slice Lesion Pathology 
Following the development of the lesioning procedure, a series of neuropathological 
assessments were performed to evaluate whether the following key pathological events 
known to occur in vivo were mimicked within slice lesions. 
 
(i) Increased astrocyte reactivity in lesion margins: Clear and even GFAP staining was 
observed throughout slices; notably, GFAP
+
 cells at lesion margins were intensively reactive 
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and hypertrophic (Figure 3A) - hallmark features of the glial scar in vivo [35]. Quantification 
of relative GFAP expression at slice lesion margins versus normal areas in the body of the 
slice (Supporting Information S2), using mean fluorescence intensity profiles (Figure 3B; n = 
6) revealed a significant intensity increase in the first 100 µm adjacent to lesion margins 
(Figure 3C). Comparatively, in regions more distant to the lesion site, GFAP
+
 astrocytes with 
normal, polygonal morphologies and lower fluorescence intensities were found. 
 
(ii) Microglial activation and infiltration into lesion sites: Lectin positive (lectin
+
) 
microglia were identified in immunostained slices and displayed activated morphologies 
within the lesion site (Figure 3A). In contrast, resting microglia located in the main body of 
slices exhibited numerous ramified processes. Counts of the numbers of lectin
+
 microglia 
within the lesion sites of slices (n = 3 per time point) revealed a significant increase in the 
number of microglia at 5 days post-lesioning (Figure 3D), with a decrease in number after 10 
days. 
 
(iii) Age/time-dependent spectrum of intrinsic nerve fiber outgrowth from lesion margins: 
After seven days of culture, nerve fiber outgrowth in young slices was extensive and 
randomly orientated (Figure 3E). By contrast the outgrowth in older slices was relatively 
limited, but also with random orientations (Figure 3F).  
 
3.3. Incorporation of Nanofiber Scaffolds over Lesions and Topographical Influences 
on Cells 
The introduction of rhodamine B into the PLA solution to fabricate fluorescent nanofibers 
had no statistically significant (two-tailed Student’s t-test) effect on either diameter (566 ± 20 
nm versus 534 ± 5 nm for non-fluorescent nanofibers) or line density (534 ± 5 fibers / mm 
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versus 566 ± 20 fibers / mm for non-fluorescent nanofibers) of nanofibers produced 
(Supporting Information S3), highlighting reproducibility in nanofiber production/processing 
for all experiments. 
Nanofibers were mounted onto acetate frames (Figure 4A), with both the fluorescence and 
alignment (Figure 4B) retained post-culture with lesioned slices (Figure 4C). The overall 
viability after incorporation of uncoated nanofiber scaffolds over lesioned slices (Figure 4D) 
remained high, with comparatively few dead cells present around the lesion site and within 
the body of the slice. Some evidence of cellular attachment to nanofibers across the lesion 
was also demonstrated (Figure 4D; white arrow heads), indicating nanofiber-slice contact 
over the culture period. 
Evaluation of the topographical influence of the nanofabricated scaffolds on cells in lesion 
sites (using uncoated versus PDL-LAM coated fibers; n ≥ 3 slices in each treatment group) 
showed that gliotic scar formation occurred similar to control slices (without nanofibers), 
with an intense region of GFAP expression at the first 100 µm of lesion margins. Following 
incorporation of uncoated nanofibers, no evidence of astrocyte attachment/alignment was 
observed (Figure 4E). In striking contrast, PDL-LAM coating of nanofibers induced 
extensive alignment of astrocytes, notably extending long thin processes (c.a. 100 - 200 µm) 
across the lesion site (Figure 4F). Extensive attachment of microglia to both uncoated (Figure 
4G) and coated nanofibers was observed over lesion sites. Notably, elongated microglia were 
visible over the entire area of the slice in contact with nanofibers.  
Quantification of the outgrowth (Supporting Information S5) and alignment of nerve fibers 
in both models of intrinsic regeneration showed that no significant nerve fiber attachment and 
outgrowth occurred (Figure 5A) following incorporation of uncoated nanofibers. In striking 
contrast, coated nanofibers enhanced nerve fiber outgrowth (Figure 5B), as confirmed by the 
mean nerve fiber outgrowth density (Figure 5C). Semi- quantitative assessment of the 
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alignment of nerve fibers on coated/uncoated nanofibers (Figure 5D) showed extensive 
alignment in both lesion models on coated nanofibers: topographical effects appeared more 
pronounced in the lesion model generated from P0 mice compared to that generated from P5 
mice, where a greater incidence of interaction between nerve fibers and materials were 
observed. Additionally, a sub-population of aligned cells displayed the morphological 
phenotypes of spinal cord interneurons (Figure 5E). Occasionally, evidence of nerve fiber 
extension coincident with elongated astrocytes was observed (Figure 5F), suggesting that a 
component of nerve fiber elongation may occur secondary to topographical cues from aligned 
astrocytes.
 
 
4. Discussion 
'Combinatorial' neural tissue engineering strategies have been suggested to be essential to 
promote various aspects of neural regeneration (such as nerve fiber regeneration, suppression 
of scar formation and immune responses, promotion of blood vessel growth) within the 
complex, multi-faceted pathology of SCI [36–40]. Such synergistic approaches have the 
potential to regenerate the injured spinal cord with varying degrees of efficacy, but none have 
been successfully translated into the clinic [41]. The full potential of combinatorial strategies 
utilising aligned nanofibers with combinations of cells and biomolecules has yet to be 
elucidated, due in part to a heavy reliance on in vivo SCI models, in the absence of high-
throughput, biologically-relevant in vitro screening models of SCI [5,42]. Two-dimensional 
reductionist tools in current widespread use e.g. microfluidic devices, have provided useful 
insights in tissue engineering, as these permit the study of fundamental, isolated aspects of 
neuronal regeneration and response to materials/biomolecules post-injury [43,44]. However, 
such in vitro models lack simulation of more complex multicellular pathology, within a 
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relevant extracellular injury environment, for detailed readouts of the biological response to 
materials.  
By contrast, we consider that the SCI model developed here can be exploited to address 
this important technological gap. First, 5-7 spinal cord slices can be routinely obtained from a 
single animal (depending on age), permitting the assessment of several conditions within the 
same batch of slices, thereby reducing experimental variability and successfully addressing 
the 3R’s principles. Second, we demonstrate that three cardinal pathological features of SCI 
in vivo can be mimicked in slice lesions, viz. post-traumatic astrogliosis, infiltration of lesions 
by activated microglia (which is broadly comparable with their acute infiltration 
characteristics in vivo) [33,48] and limited random outgrowth of nerve fibers from the lesion 
margins of slices derived from older animals. 
Third, the cellular responses observed in slice lesions following incorporation of PLA 
scaffolds or laminin-coated scaffolds are comparable to published reports in vivo, using a 
complete transecting injury model (a model used widely in experimental neurology to 
evaluate regenerative strategies). PLA is approved for clinical use by the Food and Drug 
Administration as it creates non-toxic waste products and has been widely used as a 
scaffolding material in the tissue engineering research community. Uncoated PLA scaffolds 
generally exhibit low levels of host neuronal regeneration and typically result in the 
formation of a gliotic scar at the interface between host tissue and the implant [46–49]. By 
contrast, the incorporation of laminin (or a suitable hydrogel e.g. fibrin [50]) into bridges 
increases axon regeneration and disrupts gliotic scar formation in vivo [51–54]. PDL has 
additional effects in promoting neuronal cell adhesion [55]. The decision to use both coatings 
in this study was based on reports in the literature that suggest the attachment and extension 
of neuronal processes is enhanced on PDL-LAM coated surfaces, compared to PDL alone 
[56]. The extensive attachment of microglia to nanofibers bears resemblance to the activity of 
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microglia in vivo following transplantation of nanofiber scaffolds into SCI sites [57]. The 
observation that cells in the 3-D slices can distinguish between different surface coatings 
suggests that they are able to make sophisticated choices regarding material interactions, 
within a complex environment in vitro. This highlights the high utility of our model in acting 
as a reliable 'predictor' of in vivo neural cell behaviours in response to various materials and 
surface chemistries, and hence its value as a bio-screening method. Furthermore, this 
suggests that the model can enable comparative investigations of various modifications to 
enhance nerve fiber outgrowth and alignment, including: different polymer formulations and 
other potentially efficacious substrates with an aligned topography; fiber densities and 
diameters; scaffold functionalization with therapeutic biomolecules (promoting growth or 
targeting major CNS inhibitors) and therapeutic stem/progenitor cell populations.  
The combination of the portable and lightweight nanofiber meshes with supporting acetate 
frames utilized in this study provide an innovative solution for determining the functional 
utility of various nanofiber materials. The post-collection processing of aligned nanofibers to-
date has been heavily reliant on direct collection onto 2-D glass coverslips for mechanical 
support, or alternatively, relatively thick, 3-D, more mechanically stable nanofiber meshes 
have been utilized but have additional challenges regarding cellular infiltration throughout 
the mesh thickness [1,58,59]. The supporting acetate frames: (i) provide mechanical stability 
to the nanofibers; (ii) maintain nanofiber alignment throughout culture; (iii) obviate the 
requirement for including a supporting substrate (e.g. a gel) to bridge the lesion gap, which 
would add to the complexity of the construct and increase the difficulty of interpreting the 
basic pro-regenerative readout of different nanofiber materials and surface treatments on 
multiple neural populations across injury sites; and (iv) permit a choice of nanofiber density. 
The density of nanofibers chosen in this study was fine tuned in order to: (i) provide 
sufficient nanofiber surfaces for cells to interact with without obscuring the visualization of 
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cellular events in lesions and; (ii) reduce nanofiber clumping and hence retain the 
topographical influence on neural cell populations. The development of a coating chamber 
for these studies permits the efficient and sequential coating of multiple nanofiber frames in 
suspension with different biomolecules. 
In terms of the utility of the two models of different ages chosen for our study, the 
extensive random nerve fiber outgrowth in younger slices is suited to the examination of 
axonal outgrowth on bioengineered substrates with an aligned topography. By contrast, the 
older slices that recapitulate cardinal neural features of traumatic injury in the adult CNS, 
such as limited nerve fiber outgrowth, are suited to the examination of the regeneration-
enhancing properties of novel biomaterials. The spontaneous sprouting of nerve fibers 
observed from the margins of lesioned spinal cord slices in this paradigm, which declines 
with the age of donor tissue and is influenced by pre-lesioning culture time, has been reported 
previously [31]. Further, functional assessments of regeneration i.e. electrophysiological 
recordings may provide a more detailed readout of scaffold regeneration-enhancing 
properties within this model [26]. Both models are suitable for studying the responses of the 
non-neuronal, (supporting) glial cells in lesions. The nanofiber-induced morphological 
reorganization of scar-forming astrocytes that normally form a critical barrier to nerve fiber 
regeneration reveals a potential application of the injury model for screening efficacious 
molecules and strategies that aim to disrupt the neuroglial scar, via the re-organization of 
reactive astrocyte morphology. Further, the observed infiltration of microglial cells into 
lesion sites indicates that acute inflammatory responses can be mimicked within the lesion 
sites in vitro. Their activation in SCI can be a significant barrier to the development of 
efficacious interventions as there is evidence implicating them as inhibitors of axonal 
regeneration via expression of inhibitory guidance molecules such as Netrin-1 and repulsive 
guidance molecules [60,61]. Microglial attachment to nanofibers provides an in vitro readout 
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for the optimization and testing of biocompatible materials and coatings that evoke minimal 
inflammatory responses. It also demonstrates the potential for long-term studies, where 
preliminary examination of the material degradation properties and breakdown mechanisms 
may be assessed. 
Whilst this study has utilized spinal cord as the test tissue, we consider that the high-
throughput model described here can serve as a prototype for the wider development of 
highly versatile bio-screening systems for regenerative medicine/nanotechnology. We can 
predict that these will allow for the identification of novel pro-regenerative materials for a 
wide range of tissue applications, whilst significantly reducing reliance on live animal 
experimentation, thereby accelerating the rate of discovery of nanotherapeutic agents for 
tissue engineering (Figure 6). 
 
5. Conclusion 
We have developed a multicellular, in vitro model of spinal cord injury that mimics 
multiple cardinal features of in vivo pathology. Functionalized nanofibers were able to induce 
dramatic responses in multiple cell types in the injury sites; these are comparable to those 
induced in live animal models. Our studies demonstrate the high potential of the model to 
function as a prototype screening system for promising nanotherapeutic interventions, either 
in isolation, or as part of a combinatorial treatment strategy. We can predict that the use of 
higher-throughput in vitro models of SCI, such as the one we describe here, can aid in 
overcoming a growing bottleneck in the therapeutic testing of promising new materials and 
combinatorial therapies, whilst reducing the high current reliance on live animal testing.  
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Figure 1. The production and lesioning of organotypic spinal cord slice cultures. (A) Schematic 
diagram depicting: (1) the slicing of murine spinal cords into 350 µm sections in the longitudinal 
sagittal plane and; (2) their transfer to culture inserts. (3) Following a defined culture period ‘x’, 
slices were lesioned with a double bladed scalpel by holding an elongated section (red arrow) of 
confetti (purple) together with the wall of the insert (grey) using forceps, thus keeping the slice 
stationary. (B) Photograph of the two scalpel blades, demonstrating equal blade spacing along 
the length of the blades. (C) Schematic diagram depicting: (1) electrospinning of aligned 
fluorescent poly-L,D-lactic acid nanofibers onto a parallel electrode collector; (2) the use of a 
densification tool (blue) to increase the line density of collected nanofibers; (3) attachment of 
portable acetate frames (black) containing spray adhesive to the aligned nanofibers on the 
densification tool (blue); (4) polymer coating of individual nanofiber frames in a specially 
designed chamber; (5) placement of aligned nanofiber frames over lesioned slices. 
Figure 2. Characterization of spinal cord slices and induction of focal lesions. (A) 
Representative fluorescence micrograph of a live/dead-stained slice at 6 DIV, showing 
predominantly live cells in the main body of the slice with dead cells typically found at the slice 
edges (white arrowheads). (B) A slice stained with DAPI at 2 days post-lesioning, showing clear 
demarcation of lesion margins (white broken lines). (C) Bar chart of the distances between lesion 
margins, showing the reproducibility of the lesioning procedure across different experiments, 
each involving different slice preparations and freshly assembled lesioning tools (n = 5). (D) 
Representative live/dead stained fluorescence micrograph of a slice 5 days post-lesioning reveals 
some dead cells in lesion sites (white broken lines) with high viability in the main body of the 
slice.  
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Figure 3. Characterization of the cardinal features of SCI pathology in lesioned slices. (A) 
Representative fluorescence micrograph of a lesion margin 12 days post-lesioning shows 
intensely reactive astrocytes expressing an increase in GFAP (astrocyte marker; white 
arrowheads) expression and displaying hypertrophic morphologies (red arrowheads). The 
concomitant infiltration of rounded, lectin (microglial marker) expressing, activated microglia 
into the lesion site can be seen (white arrows). (B) Line graph of the optical density profiles for 
GFAP
+
 astrocytes in lesioned slices 7 days post-lesioning (mean profile in red; n = 6) showing a 
peak in expression at lesion margins. (C) Bar graph showing a significant difference between the 
average optical densities for GFAP
+
 slices between the first 100 µm from the lesion margins and 
two adjacent regions further into the slice body (***p < 0.001; n = 6). (D) Bar graph quantifying 
numbers of lectin
+
 microglia in lesion sites at 0, 5 and 10 days post-lesioning, demonstrating a 
peak in infiltration at 5 days (*p < 0.05, **p < 0.01; n = 3 per time point). (E) Representative 
fluorescence micrograph of extensive, random outgrowth of TUJ-1
+
 (pan-neuronal marker) nerve 
fibers in lesions in young slices (P0; lesioned after 1 DIV; stained 7 day s later). (F) 
Representative fluorescence micrograph of relatively limited, random outgrowth of TUJ-1
+
 nerve 
fibers in older slices (P5; lesioned after 8 DIV; stained 7 days later). 
Figure 4. Assessment of the cellular responses in lesions after placement of nanofibers over 
injured slices. (A) Photograph of aligned fluorescent nanofibers adhered to portable acetate 
frames. (B) Representative fluorescence micrograph of aligned nanofibers adhered to portable 
acetate frames. (C) Fluorescence micrograph showing placement of portable, aligned, uncoated 
nanofibers over a lesioned slice. (D) Live/dead staining of a lesioned slice 3 days after placement 
of aligned uncoated nanofibers, verifying safe nanofiber-placement procedures (white 
arrowheads mark cells likely to be in contact with nanofibers across the lesion). (E) 
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Representative fluorescence micrograph of GFAP
+
 scar-forming astrocytes shows no interaction 
with aligned uncoated nanofibers. (F) Representative fluorescence micrograph showing the 
attachment, outgrowth and alignment of scar-forming GFAP
+
 astrocytes on poly-D-
lysine/laminin coated nanofibers across slice lesions. (G) Representative fluorescence 
micrograph showing attachment and alignment of lectin
+
 microglia to uncoated nanofibers. 
Figure 5. The effect of nanofiber coating on the outgrowth and alignment of TUJ-1
+
 nerve 
fibers. (A) Representative fluorescence micrographs of the same field showing limited 
attachment and alignment of TUJ-1
+
 nerve fibers (left-hand panel) to uncoated aligned 
nanofibers (right-hand panel) in an ‘older’ lesion model displaying limited intrinsic regeneration 
(P5 slices; lesioning and nanofiber placement after 8 DIV; fixed 7 days later). (B) Representative 
fluorescence micrographs of the same field showing extensive outgrowth and alignment of TUJ-
1
+
 nerve fibers (left-hand panel) on aligned coated nanofibers (right-hand panel) in the same 
lesion model as in (A). (C) Bar chart quantifying TUJ-1
+
 nerve fiber outgrowth density across 
lesions with un-coated and coated nanofiber (NF) treatment groups, compared to controls 
without nanofibers, in both ‘younger’ (P0 slices; lesioned after 1 DIV) and ‘older’ (P5 slices; 
lesioned after 8 DIV) slice models (***p < 0.001). (D) Bar graph showing the distributions in 
scores of TUJ-1
+
 nerve fiber alignment for both un-coated and coated nanofiber treatment groups 
in both younger and older models. (E) Representative fluorescent micrograph of a likely TUJ-1
+
 
interneuron at the lesion margins of control slices (P5) without nanofibers. (F) Fluorescence 
micrograph showing incidences of TUJ-1
+
 nerve fiber contact-guidance with aligned GFAP
+
 
astrocytes (white arrowheads) in lesions with coated nanofibers. 
Figure 6. Schematic diagram illustrating the potential screening utility of a ‘neural injury-
nanomaterial’ interface paradigm.  
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